$NEUP
Neuphoria Therapeutics Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024127032 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.667M
YoY Change
% of Gross Profit
Research & Development $1.901M $3.088M
YoY Change -38.45%
% of Gross Profit
Depreciation & Amortization $165.7K
YoY Change
% of Gross Profit
Operating Expenses $3.568M $5.468M
YoY Change -34.75%
Operating Profit -$3.568M -$5.468M
YoY Change -34.75%
Interest Expense -$243.9K
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.631M -$39.75K
YoY Change -6717.58%
Pretax Income -$937.0K -$5.507M
YoY Change -82.99%
Income Tax -$132.2K -$34.79K
% Of Pretax Income
Net Earnings -$800.0K -$5.473M
YoY Change -85.38%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 3.515B 3.118B shares 1.496B
Diluted Shares Outstanding 2.808B 1.496B

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $8.100M $8.135M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $231.1K
Receivables $116.0K
Other Receivables
Total Short-Term Assets $8.429M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $1.964K
YoY Change
Goodwill $8.904M $8.575M
YoY Change 3.84%
Intangibles $5.302M
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $14.49M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $8.429M
Total Long-Term Assets $14.49M
Total Assets $22.92M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.326M
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.552M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities $3.437K
YoY Change
Total Long-Term Liabilities $3.437K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.552M
Total Long-Term Liabilities $3.437K
Total Liabilities $5.847M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$178.8M
YoY Change
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.07M $17.23M
YoY Change
Total Liabilities & Shareholders Equity $22.92M
YoY Change

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$800.0K -$5.473M
YoY Change -85.38%
Depreciation, Depletion And Amortization $165.7K
YoY Change
Cash From Operating Activities -$4.400M -$4.430M
YoY Change -0.67%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.262M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -227.3K 612.5K
YoY Change -137.11%
NET CHANGE
Cash From Operating Activities -4.400M -4.430M
Cash From Investing Activities
Cash From Financing Activities -227.3K 612.5K
Net Change In Cash -4.627M -3.817M
YoY Change 21.22%
FREE CASH FLOW
Cash From Operating Activities -$4.400M -$4.430M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3013595
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-178781858
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-177977071
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
17070364
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
17490372
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22917207
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27649093
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1900903
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3088229
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1666824
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2379378
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
3567727
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
5467607
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3567727
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5467607
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
36096
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
86439
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-280037
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-1635
CY2024Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
2874694
CY2023Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-124558
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2630753
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-39754
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-936974
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5507361
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-132187
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-34793
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-804787
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5472568
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized After Tax
ForeignCurrencyTransactionGainLossUnrealizedAfterTax
585381
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized After Tax
ForeignCurrencyTransactionGainLossUnrealizedAfterTax
-63469
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
585381
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-63469
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-219406
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5536037
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2808140743
CY2024Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001191070
CY2024Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2024Q3 dei Amendment Flag
AmendmentFlag
false
CY2024Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q3 dei Entity Registrant Name
EntityRegistrantName
BIONOMICS LIMITED/FI
CY2024Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2024Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2024Q3 dei Document Type
DocumentType
10-Q
CY2024Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q3 dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q3 dei Entity File Number
EntityFileNumber
001-41157
CY2024Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
C3
CY2024Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Greenhill Road
CY2024Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Eastwood, SA
CY2024Q3 dei Entity Address Country
EntityAddressCountry
AU
CY2024Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
5063
CY2024Q3 dei City Area Code
CityAreaCode
+61
CY2024Q3 dei Local Phone Number
LocalPhoneNumber
8 8150 7400
CY2024Q3 dei Security12b Title
Security12bTitle
American Depositary Shares
CY2024Q3 dei Trading Symbol
TradingSymbol
BNOX
CY2024Q3 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q3 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q3 dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Bankruptcy Proceedings Reporting Current
EntityBankruptcyProceedingsReportingCurrent
true
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3514922864
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8082410
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2808140743
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1495995035
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1495995035
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
17490372
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
409
CY2024Q3 bnox Share Issue Cost
ShareIssueCost
227747
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
26736
CY2024Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-585381
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-804787
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
17070364
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
22010563
CY2023Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
500000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
612538
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
140448
CY2023Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
63469
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5472568
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
17227512
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-804787
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5472568
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
26736
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
132739
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
165713
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
165909
CY2024Q3 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-19528
CY2023Q3 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-36166
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2966245
CY2024Q3 bnox Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
91551
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12608109
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
115960
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
126884
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
231108
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
458765
CY2024Q3 us-gaap Assets Current
AssetsCurrent
8429478
CY2024Q2 us-gaap Assets Current
AssetsCurrent
13193758
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1964
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1994
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5301839
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5467522
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
197447
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
216975
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
82491
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
78826
CY2024Q3 us-gaap Goodwill
Goodwill
8903988
CY2024Q2 us-gaap Goodwill
Goodwill
8690018
CY2024Q3 us-gaap Assets
Assets
22917207
CY2024Q2 us-gaap Assets
Assets
27649093
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1325994
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2243662
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1095838
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1463421
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
129881
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
121990
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2551713
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3829073
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
89469
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
117628
CY2024Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
679313
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
587762
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
831324
CY2024Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
963540
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1691587
CY2024Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
4657832
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3437
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2886
CY2024Q3 us-gaap Liabilities
Liabilities
5846843
CY2024Q2 us-gaap Liabilities
Liabilities
10158721
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3117662864
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3117662864
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2384539964
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2384539964
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
198280436
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
198481038
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2428214
CY2023Q3 bnox Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
124558
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-233044
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-67319
CY2024Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10924
CY2023Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
16252
CY2024Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-227657
CY2023Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-427316
CY2024Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-917668
CY2023Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
880613
CY2024Q3 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-367583
CY2023Q3 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-704745
CY2024Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-20268
CY2023Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-36393
CY2024Q3 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-132216
CY2023Q3 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-34793
CY2024Q3 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
551
CY2023Q3 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
331
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4433063
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4429800
CY2024Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
227747
CY2024Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
409
CY2023Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2024Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6261514
CY2024Q3 bnox Stock Issued Pursuant To Subscription Receivable
StockIssuedPursuantToSubscriptionReceivable
0
CY2023Q3 bnox Stock Issued Pursuant To Subscription Receivable
StockIssuedPursuantToSubscriptionReceivable
5648976
CY2024Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-227338
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
612538
CY2024Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
138367
CY2023Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-152773
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4660401
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3817262
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12686935
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12181944
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8164901
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8211909
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8082410
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8135059
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
82491
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
76850
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8164901
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8211909
CY2024Q3 bnox Working Capital Deficit
WorkingCapitalDeficit
5900000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-178800000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8100000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-800000
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-15500000
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4400000
CY2024Q3 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of revenue, expenses, and certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company’s collaboration agreements, the collectability of receivables, impairment evaluation for goodwill and intangible assets, and the fair values of contingent consideration and warrants. Actual results may differ from such estimates.</span></p>
CY2024Q3 bnox Research And Development Incentives Receivable
ResearchAndDevelopmentIncentivesReceivable
100625
CY2024Q2 bnox Research And Development Incentives Receivable
ResearchAndDevelopmentIncentivesReceivable
96154
CY2024Q3 bnox Gst Receivables
GSTReceivables
14059
CY2024Q2 bnox Gst Receivables
GSTReceivables
30444
CY2024Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
1276
CY2024Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
286
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
115960
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
126884
CY2021Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2024Q3 bnox Lease Payments Percenatage
LeasePaymentsPercenatage
0.03
CY2024Q3 us-gaap Lessor Operating Lease Renewal Term
LessorOperatingLeaseRenewalTerm
P1Y
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
145186
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
182584
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
327770
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
108420
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
219350
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
129881
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
89469
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
219350
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.035
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M18D
CY2024Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
14313
CY2023Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
13996
CY2024Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
16121
CY2023Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
15724
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
30434
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
29720
CY2024Q2 us-gaap Goodwill
Goodwill
8690018
CY2024Q3 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-213970
CY2024Q3 us-gaap Goodwill
Goodwill
8903988
CY2023Q2 us-gaap Goodwill
Goodwill
8694186
CY2023Q3 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
119490
CY2023Q3 us-gaap Goodwill
Goodwill
8574696
CY2024Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P20Y
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
719235
CY2024Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
648858
CY2024Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
78649
CY2024Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
311172
CY2024Q3 bnox Accrued Professional And Consulting Fees Current
AccruedProfessionalAndConsultingFeesCurrent
229988
CY2024Q2 bnox Accrued Professional And Consulting Fees Current
AccruedProfessionalAndConsultingFeesCurrent
297780
CY2024Q3 bnox Research And Development Expenses
ResearchAndDevelopmentExpenses
0
CY2024Q2 bnox Research And Development Expenses
ResearchAndDevelopmentExpenses
134910
CY2024Q3 bnox Eda Loan
EDALoan
34660
CY2024Q2 bnox Eda Loan
EDALoan
33120
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
33306
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
37581
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1095838
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1463421
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P5Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
110449330
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.12
CY2024 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y2M4D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
-13015000
CY2024Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Other Share Increase Decrease In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice
0.01
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
97434330
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.13
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y8M26D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
79909138
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.16
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M14D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P1Y2M12D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
0
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.141
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.006
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-132187
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-34793
CY2024Q3 us-gaap Payment For Management Fee
PaymentForManagementFee
15000
CY2024Q3 bnox Fundraising Proceeds Percentage
FundraisingProceedsPercentage
0.05
CY2024Q3 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
100000
CY2024Q3 us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 16. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ironwood Pharmaceuticals, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2012, the Company entered into a research and license agreement with Ironwood Pharmaceuticals, Inc. (“Ironwood”) pursuant to which Ironwood was granted worldwide development and commercialization rights for BNC210. In November 2014, the parties mutually agreed to terminate this license agreement, reverting all rights to BNC210 back to the Company. The sole obligation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to Ironwood is to pay Ironwood low to mid-single digit royalties on the net sales of BNC210, if commercialized. It is not practicable to estimate the future payments of any such royalties that may arise due to the stage of development of BNC210.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Severance Obligation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a contingent liability in relation to the employment agreement with Dr. Spyros Papapetropoulos for severance pay of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">787,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Depositary Agreement with Citibank</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the Company planning to affect a redomiciliation by a scheme of arrangement under Part 5.1 of the Australian Corporations Act which would change the jurisdiction of the holding company of the Bionomics Group from Australia to the United States, we will terminate the ADR Depositary Agreement with Citibank. We may be required to pay significant additional fees for the withdrawal or termination of this program and are not able to estimate what those fees will be.</span></p>
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-127032-index-headers.html Edgar Link pending
0000950170-24-127032-index.html Edgar Link pending
0000950170-24-127032.txt Edgar Link pending
0000950170-24-127032-xbrl.zip Edgar Link pending
bnox-20240930.htm Edgar Link pending
bnox-20240930.xsd Edgar Link pending
bnox-ex31_1.htm Edgar Link pending
bnox-ex31_2.htm Edgar Link pending
bnox-ex32_1.htm Edgar Link pending
bnox-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
bnox-20240930_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable